Giovanni Mori

Does acute pyelonephritis skew outcomes in registrational trials of novel antibiotics for complicated urinary tract infections? A systematic review and meta-analysis

Giovanni Mori, Tommaso Ceccato, Simone Botti, Simone Giuliano et autres

BACKGROUND: Acute pyelonephritis (AP) and complicated urinary tract infections (cUTIs) are pooled in registrational RCTs of new antibiotics. We assessed whether outcomes differ between subtypes and which component of the composite endpoint drives any difference. METHODS: Across ten registrational RCTs we estimated …

it, no, dk (code pays fourni par la source)

Capnocytophaga canimorsus Meningoencephalitis Diagnosed by PCR-Free Shotgun Metagenomics of CSF with Read-Level blaOXA-347 Detection: A Case Report

Giovanni Lorenzin, Marco de Bertoldi, Giulia Bellozzi, Matteo Carlin et autres

it (code pays fourni par la source)

Long-acting injectable cabotegravir/rilpivirine in a pregnant woman living with HIV with hyperemesis gravidarum:a case report and review of literature

Emanuela Lattuada, Andrea Delama, Alessandro Castelli, Giovanni Mori et autres

IntroductionLong-acting injectable cabotegravir/rilpivirine (CAB/RPV LA) represents a novel antiretroviral strategy that bypasses gastrointestinal absorption, potentially advantageous in pregnant individuals unable to tolerate oral therapy. However, its use in pregnancy remains off-label due to limited pharmacokinetic (PK), safety and clinical outcome data.Case presentationWe …

it (code pays fourni par la source)

Bridging the gap in bloodstream infection management: a survey among non-infectious disease physicians

Giovanni Mori, Emanuela Zandonà, Annalisa Campomori, Claudio Scarparo et autres

Abstract Objective Bloodstream infections (BSIs) significantly impact morbidity and mortality. Despite emerging evidence supporting optimal management, substantial variability persists among non-infectious disease (ID) physicians. This study assessed non-ID physicians’ knowledge and attitudes in BSI management, identifying critical gaps to inform antimicrobial stewardship …

it (code pays fourni par la source)

Rezafungin Utilisation in Real Life— FungiScope Results From Europe and the United States

Ilana Reinhold, Giovanni Mori, Massimiliano Lanzafame, Alessandro Limongelli et autres

BACKGROUND: Rezafungin, a novel echinocandin with once-weekly intravenous dosing, offers potential advantages for outpatient parenteral antifungal therapy (OPAT) in invasive candidiasis (IC). While clinical trial data support its efficacy and safety, real-world experience remains limited. METHODS: A retrospective analysis of patients treated …

de, us, it, es (code pays fourni par la source)

WISE (Web-based Infectious Support for the Elderly) Initiative: Improving Infectious Disease Management in LTCFs—Experience From Northern Italy

Giovanni Mori, Alessia Prezzavento, Sebastiano Rizzardo, Norberto Gusman et autres

it, us, bd, cn (code pays fourni par la source)

Risk stratification and impact of donor type on breakthrough invasive fungal infections in haematopoietic cell transplant with post-transplant cyclophosphamide and mould-active prophylaxis

Matteo Chiurlo, Laura Galli, Francesca Farina, Andrea Acerbis et autres

it (code pays fourni par la source)

Long-term Safety and Effectiveness of Rezafungin Treatment in Candidemia and Invasive Candidiasis: Results From an Early Access Program in Italy and Germany

Filippo Trapani, Giulio Viceconte, Valentina Morena, Giusy Tiseo et autres

Abstract Outcomes are reported for 6 adults receiving rezafungin for chronic, hard-to-treat, invasive candidiasis (including Candida parapsilosis) during an early access program. Rezafungin was well tolerated and administered via once-weekly outpatient intravenous infusion for up to 39 weeks during the program, enabling …

it, au, de (code pays fourni par la source)

Advances in HIV Treatment: Long-Acting Antiretrovirals and the Path Toward a Cure

Massimiliano Lanzafame, Giovanni Mori, Sandro Vento

Long-acting antiretroviral therapy (LA-ART) represents an important advancement in HIV care as it has considerably reduced the frequency of dosing and therefore improved adherence [...].

it, kh (code pays fourni par la source)

Short-Cycle Therapy with Bictegravir/Emtricitabine/Tenofovir Alafenamide in a Small Cohort of Virally Suppressed People Living with HIV: A Long-Term Follow-Up

Massimiliano Lanzafame, Emanuela Lattuada, Andrea Delama, Giovanni Mori et autres

BACKGROUND: Antiretroviral triple therapy has considerably reduced morbidity and mortality in people living with HIV and is the standard-of-care treatment. However, it is lifelong and linked to long-term side effects and adherence problems. METHODS: Here, we report long-term virological and immunological outcome …

it, kh (code pays fourni par la source)

High malaria parasitemia in an Italian man and severe delayed hemolytic anemia

Massimiliano Lanzafame, Giovanni Mori, E Lattuada, Claudio Scarparo

Parenteral artesunate has become the choice treatment of cases of high parasitemia malaria. We report the case of an Italian man with a high malaria parasitemia who promptly improved with intravenous artenusate, but who developed a delayed severe hemolytic anemia associated with …

it (code pays fourni par la source)

When an underestimated zoonosis and antimicrobial resistance collide: Corynebacterium ulcerans

Giovanni Mori, Giulia Errico, Sara Giancristoforo, Donatella Visentin et autres

In the European region, diphtheria is now rarely suspected in patients presenting with upper respiratory tract symptoms. Corynebacterium ulcerans is the underestimated zoonosis that is replacing C. diphtheria infections in industrialized countries, but extensive human and animal prevalence studies are lacking. The …

it (code pays fourni par la source)